NASDAQ:IBRX ImmunityBio - IBRX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $4.33 0.00 (0.00%) (As of 02/6/2023 12:00 AM ET) Add Compare Share Share Today's Range$4.25▼$4.5150-Day Range$3.78▼$6.7752-Week Range$2.60▼$7.85Volume1.64 million shsAverage Volume1.78 million shsMarket Capitalization$1.73 billionP/E RatioN/ADividend YieldN/APrice Target$9.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media ImmunityBio MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside107.9% Upside$9.00 Price TargetShort InterestBearish27.61% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.00) to ($0.96) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.65 out of 5 starsMedical Sector853rd out of 1,027 stocksBiological Products, Except Diagnostic Industry137th out of 169 stocks 3.5 Analyst's Opinion Consensus RatingImmunityBio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.00, ImmunityBio has a forecasted upside of 107.9% from its current price of $4.33.Amount of Analyst CoverageImmunityBio has received no research coverage in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted27.61% of the float of ImmunityBio has been sold short.Short Interest Ratio / Days to CoverImmunityBio has a short interest ratio ("days to cover") of 14.1, which indicates bearish sentiment.Change versus previous monthShort interest in ImmunityBio has recently increased by 0.89%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldImmunityBio does not currently pay a dividend.Dividend GrowthImmunityBio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IBRX. Previous Next 1.4 News and Social Media Coverage News SentimentImmunityBio has a news sentiment score of -0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for ImmunityBio this week, compared to 1 article on an average week.Search Interest19 people have searched for IBRX on MarketBeat in the last 30 days. This is an increase of 19% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added ImmunityBio to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ImmunityBio insiders have not sold or bought any company stock.Percentage Held by Insiders79.73% of the stock of ImmunityBio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.86% of the stock of ImmunityBio is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ImmunityBio are expected to grow in the coming year, from ($1.00) to ($0.96) per share. Previous Next See Top Rated MarketRank™ Stocks Here About ImmunityBio (NASDAQ:IBRX) StockImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.Read More Receive IBRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmunityBio and its competitors with MarketBeat's FREE daily newsletter. Email Address IBRX Stock News HeadlinesFebruary 2, 2023 | americanbankingnews.comImmunityBio (NASDAQ:IBRX) Stock Price Up 4.2%January 19, 2023 | finance.yahoo.comImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to RegistrationFebruary 6, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...December 12, 2022 | finance.yahoo.comImmunityBio Announces $157 Million Financing From Nant and Institutional InvestorNovember 17, 2022 | finance.yahoo.comImmunityBio to Participate in 34th Annual Piper Sandler Healthcare ConferenceOctober 27, 2022 | finance.yahoo.comImmunityBio to Participate in the Jefferies London Healthcare ConferenceOctober 19, 2022 | finance.yahoo.com15 Best Drug Stocks to Buy Now - Yahoo FinanceOctober 17, 2022 | seekingalpha.comImmunityBio: PDUFA Pending (NASDAQ:IBRX) - Seeking AlphaFebruary 6, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...October 11, 2022 | finance.yahoo.comIMMUSE™ Interactive Masterclass Explores Immune System Balance To Build Lifelong Resilience - Yahoo FinanceSeptember 15, 2022 | seekingalpha.comHeartBeam, NeuroBo top healthcare gainers; Shuttle, Omeros lead losers' pack - Seeking AlphaSeptember 14, 2022 | latimes.comExperimental COVID-19 vaccine may outsmart future coronavirus variants - Los Angeles TimesSeptember 12, 2022 | nasdaq.comIBRX Makes Bullish Cross Above Critical Moving AverageSeptember 7, 2022 | bloomberg.comPandemic Readiness Lobby Draws In Biotech, Government Members - BloombergSeptember 4, 2022 | nasdaq.comImmunityBio, Inc.'s (NASDAQ:IBRX) most bullish insider, Top Key Executive Patrick Soon-Shiong must be pleased with the recent 4.9% gainAugust 10, 2022 | nasdaq.comCelldex Therapeutics (CLDX) Reports Q2 Loss, Lags Revenue Estimates - NasdaqAugust 4, 2022 | nasdaq.comPieris Pharmaceuticals (PIRS) Reports Q2 Loss, Lags Revenue Estimates - NasdaqAugust 3, 2022 | benzinga.comImmunityBio shares are trading higher after Jefferies initiated coverage on the stock with a Buy rating a - BenzingaJuly 29, 2022 | benzinga.comDaily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In K - BenzingaJuly 28, 2022 | businesswire.comImmunityBio Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma In Situ - Business WireJuly 28, 2022 | finance.yahoo.comImmunityBio Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma In SituJuly 27, 2022 | finance.yahoo.comFauci on needing a second generation of COVID vaccines: 'We have multiple variants of concern ... And it's getting more complicated' - Yahoo FinanceJune 7, 2022 | finance.yahoo.comImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting - Yahoo FinanceJune 6, 2022 | businesswire.comImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting - Business WireJune 6, 2022 | finance.yahoo.comImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual MeetingJune 2, 2022 | seekingalpha.comImmunityBio: Shifting Gears After Long-Awaited BLA Submission (NASDAQ:IBRX) - Seeking AlphaMay 23, 2022 | businesswire.comImmunityBio Submits Biologics License Application for N-803 Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ - Business WireSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive IBRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmunityBio and its competitors with MarketBeat's FREE daily newsletter. Email Address IBRX Company Calendar Last Earnings11/08/2022Today2/06/2023Next Earnings (Estimated)2/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IBRX CUSIPN/A CIK1326110 Webimmunitybio.com Phone(858) 633-0300FaxN/AEmployees587Year FoundedN/APrice Target and Rating Average Stock Price Forecast$9.00 High Stock Price Forecast$10.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+107.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-346,790,000.00 Net Margins-71,743.44% Pretax Margin-71,911.30% Return on EquityN/A Return on Assets-104.67% Debt Debt-to-Equity RatioN/A Current Ratio2.02 Quick Ratio2.02 Sales & Book Value Annual Sales$930,000.00 Price / Sales1,863.76 Cash FlowN/A Price / Cash FlowN/A Book Value($0.61) per share Price / Book-7.10Miscellaneous Outstanding Shares400,300,000Free Float81,142,000Market Cap$1.73 billion OptionableOptionable Beta1.56 Key ExecutivesPatrick Soon-ShiongExecutive Chairman & Global Chief Medical OfficerRichard AdcockPresident, Chief Executive Officer & DirectorLeonard S. SenderChief Operating OfficerDavid SachsChief Financial OfficerJohn H. LeeChief Medical OfficerKey CompetitorsRecursion PharmaceuticalsNASDAQ:RXRXTwist BioscienceNASDAQ:TWSTArcellxNASDAQ:ACLXReplimune GroupNASDAQ:REPLAdaptive BiotechnologiesNASDAQ:ADPTView All CompetitorsInsiders & InstitutionsSimplex Trading LLCSold 59,700 shares on 2/2/2023Ownership: 0.000%SG Americas Securities LLCSold 80,262 shares on 2/2/2023Ownership: 0.004%Bank of Montreal CanBought 300 shares on 2/1/2023Ownership: 0.000%Zurcher Kantonalbank Zurich Cantonalbank Bought 5,392 shares on 2/1/2023Ownership: 0.005%Mayflower Financial Advisors LLCBought 16,510 shares on 1/25/2023Ownership: 0.004%View All Institutional Transactions IBRX Stock - Frequently Asked Questions Should I buy or sell ImmunityBio stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ImmunityBio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" IBRX shares. View IBRX analyst ratings or view top-rated stocks. What is ImmunityBio's stock price forecast for 2023? 1 Wall Street analysts have issued 12 month price objectives for ImmunityBio's shares. Their IBRX share price forecasts range from $8.00 to $10.00. On average, they predict the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 100.4% from the stock's current price. View analysts price targets for IBRX or view top-rated stocks among Wall Street analysts. How have IBRX shares performed in 2023? ImmunityBio's stock was trading at $5.07 at the beginning of 2023. Since then, IBRX stock has decreased by 11.4% and is now trading at $4.49. View the best growth stocks for 2023 here. When is ImmunityBio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 14th 2023. View our IBRX earnings forecast. How were ImmunityBio's earnings last quarter? ImmunityBio, Inc. (NASDAQ:IBRX) posted its earnings results on Tuesday, November, 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.23) by $0.05. The company earned $0.12 million during the quarter, compared to the consensus estimate of $0.03 million. What is ImmunityBio's stock symbol? ImmunityBio trades on the NASDAQ under the ticker symbol "IBRX." Who are ImmunityBio's major shareholders? ImmunityBio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Bank of Montreal Can (0.00%), Simplex Trading LLC (0.00%), Zurcher Kantonalbank Zurich Cantonalbank (0.00%), SG Americas Securities LLC (0.00%), Mayflower Financial Advisors LLC (0.00%) and Mayflower Financial Advisors LLC (0.00%). Insiders that own company stock include Barry J Simon, Cheryl Cohen and Richard Adcock. View institutional ownership trends. How do I buy shares of ImmunityBio? Shares of IBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ImmunityBio's stock price today? One share of IBRX stock can currently be purchased for approximately $4.49. How much money does ImmunityBio make? ImmunityBio (NASDAQ:IBRX) has a market capitalization of $1.80 billion and generates $930,000.00 in revenue each year. How many employees does ImmunityBio have? The company employs 587 workers across the globe. How can I contact ImmunityBio? ImmunityBio's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The official website for the company is immunitybio.com. The company can be reached via phone at (858) 633-0300 or via email at investors@nantkwest.com. This page (NASDAQ:IBRX) was last updated on 2/6/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.